Welcome, ladies and gentlemen, to the Second Quarter 2025 Earnings Conference Call for Organogenesis Holdings, Inc. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including the Item 1A, Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with the generally accepted accounting principles or GAAP. We generally refer to this as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Gary S. Gillheeney, Sr., Organogenesis Holdings President, Chief Executive Officer and Chair of the Board. Please go ahead, sir.

Thank you, operator and welcome, everyone, to Organogenesis Holdings Second Quarter 2025 Earnings Conference Call. I am joined on the call today by Dave Francisco, our Chief Financial Officer. Let me start with a brief agenda of what we will cover during our prepared remarks. I'll begin with an overview of our second quarter revenue results and provide an update on key operating and strategic developments in recent months, and then Dave will provide you with an in-depth review of our second quarter financial results, our balance sheet and financial condition at quarter end as well as our financial guidance for 2025, which we updated in our press release this afternoon. Then we will open up the calls for questions. Beginning with a review of our revenue results in Q2, we delivered sales results within the guidance range outlined on our first-quarter call, driven by better-than-expected growth in our Surgical & Sports Medicine products and sales of Advanced Wound Care products that came in at the lower end of our expectations. Our second quarter Advanced Wound Care results reflect the expected disruption in customer demand and ordering patterns related to the delay in the effective date of the final LCD for skin substitute grafts and cellular tissue-based products for the treatment of DFUs and VLUs until January 1, 2026. Our team's second quarter execution and focus on engagement, education and support helped our customers navigate a confusing and challenging environment. While the delay in the effective date for the final LCD fueled even more aggressive pricing strategies from our competitors, our team remains committed to building upon our deep customer relations and promoting access to existing and recently launched products. Last month, CMS announced the proposed Medicare physician fee schedule and outpatient prospective payment systems for calendar year 2026. This is a watershed moment for this industry and the most impactful development in more than a decade. We applaud the proposed new payment approach for skin substitutes as we have long advocated for an integrated coverage and payment policy to address rapid escalation of Medicare spending while ensuring patients have access to the products best suited to their care. Organogenesis has more than 40 years of experience and pioneered the use of cellular and tissue-based products for wound treatment and we have spent the past several years leading key stakeholders who share our patient-focused values to inform policymakers and advocate for reform that will increase access, improve outcomes and curb the rampant waste and abuse in the space. We have long supported many of the points included in the proposed rules, notably a per square centimeter payment methodology based on FDA classification for skin substitutes covering all ASP sites of care as well as the hospital outpatient setting, bringing a much-needed consistent payment approach. Exploitation of the current ASP-based payment system has resulted in excessive and unsustainable spending these past few years. Closing this loophole and shifting away from the ASP model will bring stability to the market and push spending on dehydrated placentals in line with appropriate utilization. And we are pleased that the proposed FDA classification categories ensures patients will have access to appropriate therapies and encourage innovation in the space. As the population ages and more people face the prospect of chronic wounds associated with diabetes and other comorbid conditions, it's imperative that the industry reignite its innovation engine to deliver advanced regenerative technologies that will speed healing and reduce the total cost of care. We believe the proposed rule, if finalized, will support these goals while bringing long-term stabilization to the skin substitute markets. Importantly, we are pleased that CMS has recognized the clinical differentiation of Premarket Approval or PMA products that outline steps to expand access to these healing technologies. PMA products such as Apligraf and Dermagraft have been proven to reduce life-threatening amputations and costly complications associated with DFUs and VLUs. The proposed rules will encourage the continued development of PMA products that will greatly benefit both clinicians and patients. As the public comment period opens, we remain committed to engage with CMS and other stakeholders to refine and enhance the proposed rules that will expand access to appropriate therapies for patients while reducing the overall cost to Medicare. With the payment and coverage changes expected to be implemented in 2026, we believe we are better positioned to continue to lead the space with highly innovative, highly efficacious products that deliver on our mission of advancing healing and recovery beyond our customers' expectations. Before turning the call over to David, I want to provide updates on key strategic focuses for our company. We believe gathering robust and comprehensive clinical and real-world evidence is an essential component of developing a competitive product portfolio and driving further penetration in the markets where we compete. We expect to submit published clinical data supporting PuraPly AM for DFU and Affinity for VLU to the MACs by the established deadline of November 1, 2025. We have been preparing our organization to succeed in a new world that is coming to fruition by investing to optimize our industry-leading portfolio of healing technologies. In May, we marked the expansion of our biomanufacturing capabilities at our new facility in Smithfield, Rhode Island, welcoming the governor and other state and civic leaders to share our plans for the site. When completed, the Smithfield facility will support the reintroduction of Dermagraft, a PMA-approved product for the treatment of DFUs and TransCyte, a PMA-approved bioengineered cellular tissue scaffold for the treatment of deep second- and third-degree burns as well as the introduction of FortiShield, a biosynthetic transitional wound matrix for the treatment of second-degree burns and surgical wounds. We believe the added manufacturing capacity and portfolio expansion will further enhance our long-term growth and margin profile, create additional stakeholder value and positively impact more people's lives. With respect to our ReNu program, we remain on plan for submission for ReNu by the end of this year, which, if approved, will further enrich our already robust regenerative portfolio. All patients completed the second Phase III study and we remain on track to share publicly the top line data results from the study in September of 2025. Our timeline continues to target completion of the final clinical study report required for the BLA submission in the fourth quarter, which has us on track for a modular BLA submission by the end of 2025. We continue to believe in the potential of ReNu to address the need for more than 30 million Americans suffering from symptomatic knee osteoarthritis. This is a defining moment for the industry and an exciting opportunity for Organogenesis to serve more patients. We see our vision for skin substitutes in wound care becoming a reality following years of advocating for health policy reform to ensure patient access to the most appropriate products while achieving significant cost savings to Medicare. We believe we are positioned to win going forward with our comprehensive portfolio, including products from all FDA classifications. We have a development engine fueling new innovation and the capacity to launch and reintroduce products and a transformational opportunity with ReNu. With that, let me turn the call over to Dave.

Thanks, Gary. I'll start by reviewing our second quarter financial results. Unless noted otherwise, all growth rates mentioned during our remarks are year-over-year. Net product revenue for the second quarter was $100.8 million, a decrease of 23%. As Gary noted, these results were within the expectations set during our Q1 call, which projected total revenue between $100 million and $110 million. Advanced Wound Care net product revenue for the second quarter was $92.7 million, down 25%. The commercial team performed well during this period, building momentum at the end of Q2 despite the delayed effective date of the LCD, which intensified competitive pricing strategies. Net product revenue from Surgical & Sports Medicine products for the second quarter was $8.1 million, an increase of 16%. Total revenue for the second quarter included $0.2 million in grant income from the Rhode Island Life Sciences Hub, which helped offset employee-related costs at our Smithfield facility. This is compared to no impact in the same period last year, and we expect grant income to be negligible in 2025. Gross profit for the second quarter was $73.1 million, representing 73% of net product revenue, compared to 78% last year. Gross profit was negatively affected mainly due to lower revenue relative to fixed costs and the expiration of excess product linked to the delayed implementation of the LCD and related uncertainties. Operating expenses for the second quarter were $113.6 million, down from $144.1 million last year, a decrease of $30.5 million or 21%. Excluding cost of goods sold of $27.6 million in the second quarter and $29.2 million last year, our non-GAAP operating expenses for the second quarter were $86 million compared to $114.9 million the previous year, a decline of $29 million or 25%. The year-over-year change in operating expenses, excluding cost of goods sold, was influenced by a $22.8 million write-down of certain nonrecurring costs in the second quarter of 2024 versus $1.7 million in the second quarter of 2025, along with reductions in research and development and SG&A expenses, which fell by 33% and 4%, respectively. The operating loss for the second quarter was $12.6 million compared to an operating loss of $13.9 million last year, a decrease of $1.3 million. Excluding noncash amortization and the write-down of certain nonrecurring costs in both periods, our non-GAAP operating loss was $10 million compared to an income of $9.7 million last year. The GAAP net loss for the second quarter was $9.4 million compared to a net loss of $17 million last year, a decrease of $7.6 million. The net loss to common for the second quarter was $12.2 million compared to a net loss of $17 million last year. This includes the impact of the cumulative dividend and the noncash accretion to redemption value on our convertible preferred stock. The adjusted EBITDA loss for the second quarter was $3.6 million compared to an adjusted EBITDA income of $15.6 million last year. Turning to the balance sheet, as of June 30, 2025, the company had $73.7 million in cash, cash equivalents, and restricted cash with no outstanding debt, down from $136.2 million in cash, cash equivalents, and restricted cash as of December 31, 2024, also with no debt. Now, regarding our 2025 revenue guidance updated in this afternoon's press release, we now expect net revenue of between $480 million and $510 million for the 12 months ending December 31, 2025, which indicates a year-over-year change ranging from flat to an increase of 6%. The 2025 net revenue guidance assumes net revenue from Advanced Wound Care products between $450 million and $475 million, reflecting a year-over-year change from a 1% decline to a 5% increase. Net revenue from Surgical & Sports Medicine products is expected to be between $30 million and $35 million, indicating a year-over-year increase of 6% to 23%. The anticipated revenue growth in the second half of 2025 will be supported by our newly launched in-licensed products, which are well positioned in the current market. We have narrowed our total revenue guidance range based on our performance in the first half of 2025 and our refined expectations for the remaining quarters. Regarding our profitability and EBITDA guidance, the company now anticipates a GAAP net loss ranging from $6.4 million to a net income of $16.4 million, a revision from the previously expected net income of $4.7 million to $34 million. We expect EBITDA to fall between $6.2 million and $37 million, compared to the earlier guidance of $20 million to $59.6 million. Non-GAAP adjusted net income is now projected to be between $5.5 million and $28.3 million versus $15.3 million and $44.6 million previously. Adjusted EBITDA is now expected between $31.1 million and $61.9 million compared to the prior estimate of $43.6 million to $83.2 million. Additionally, for modeling purposes, we project third-quarter revenue to be around $130 million to $145 million. Our profitability guidance for 2025 now predicts gross margins in the range of approximately 74% to 76%, down from 78% to 79% previously. This updated gross margin range considers the expected impact of product mix changes in our in-licensed brands during the second half of 2025. We expect GAAP operating expenses, excluding cost of goods sold, to remain flat to increase by 1% year-over-year. Excluding noncash intangible amortization of about $3.4 million, the nonrecurring FDA payment of $4.6 million related to our ReNu BLA filing, and the $8.3 million write-down of assets in the first half, our total non-GAAP operating expenses are projected to rise by 3% to 4% year-over-year, a change from the earlier range of 5% to 7%. With that, I'll turn the call over to the operator to begin the Q&A session.

Maybe we could start with the CMS proposal for 2026. It is a radical change from what we've seen. And I believe the proposal was set at about $125 and change per square centimeter, if I'm not mistaken. Maybe, Gary, you could talk about kind of how you see ORGO fitting within that structure as it starts the year in 2026. And what are your expectations for the market from, let's say, today through the back half of '25? And then what changes in '26 with that proposal and how the market may change?

Sure. I'd be happy to. So as you know, we've been advocating for this type of payment reform for years, literally years. So it is a transformational event for the industry and a real opportunity for our products and the Organogenesis organization. We agree with the CMS approach of setting tiers and those tiers based on clinical differentiation and relative resource cost. They've broken them out based on FDA classifications where data and evidence really matters. So we feel great about this change. And the fact that it's also in HOPD, it’s not just in the ASP sites of care. It’s now opened up the HOPD market to larger, more complex wounds where we are the leader in that space, that just gives more opportunity for folks to utilize our technologies like Apligraf and soon to be released Dermagraft. So Apligraf is reimbursed today at $30 per square centimeter, and the current proposal at $125 would be a significant change. It would eliminate any of the disincentives financially to use the product and put it on a level playing field. But what we really appreciate is CMS establishing these tiers, and we expect that we'll be lobbying for different payment rates based on those tiers. So Apligraf and Dermagraft and other PMA products will have the appropriate reimbursement based on the evidence and relative resource cost to produce those products. So this is very exciting for us and very exciting for the industry. As it relates to the market, today, Apligraf represents about 3% of the units sold; believe it or not, a PMA product with arguably the best evidence in the space has about 3% of the market. And we see that significantly changing in 2026. 510(k) products as well. Our PuraPly product is priced below the $125 per square centimeter today, so we would see an enhancement in that product and more utilization going forward. And then a level playing field for all the amnions. So there wouldn’t be a significant price advantage going forward, levels the playing field. So we see a lot of reasons why '26 is going to be extremely positive for us. The rest of '25, I think we've seen in Q2, we've seen some aggressive pricing. We think that's going to continue and get worse at the end of the year. I assume there'll be a lot of discounting and inventory sales. Anyone who's got a lot of inventory at higher prices are going to need to move those products and we expect to see aggressive pricing. But for us, we've seen strong momentum coming out of the second quarter. Dave will talk a little bit about that. That momentum is continuing, both in accounts and in revenue. And we have a couple of new products that we've launched that will compete extremely well in this market as we bridge to 2026.

Yes, to follow up on that, your guidance reduction appears to be around $12.5 million at the midpoint. Given the results today, Dave, do you think you've sufficiently accounted for this aggressive behavior in the second half of the year with the reduction of the AWC segment for the remainder of the year?

Yes, Ryan, thank you for the question. As Gary mentioned, we exited Q2 at the low end but with considerable momentum. We have recently launched some new products, which are essential for succeeding in this market. We believe these products will significantly contribute in the second half of the year. While there may be some challenges in the latter part of Q4, we think we've adequately prepared for that. We expected some fluctuations when we initially provided guidance due to the unique market conditions. Therefore, we decided to lower the top end of our forecast, considering we have two quarters behind us and two ahead. We feel confident about the low end, especially based on the performance we observed at the end of the second quarter.

Okay. Last one for me, and I'll hop back in queue. Gary, I don't think I heard you. You may not want to say the timing of the Dermagraft reintroduction. Can you be more specific? Or for competitive purposes, are you not saying?

Well, we can give you a sense. We think that by the second half of '27 that we'll have the opportunity to launch Dermagraft.

We are currently showing no remaining questions in the queue. A question is raised from Ross Osborn with Cantor Fitzgerald.

This is Matt Park on for Ross today. I guess something right n ReNu. As you guys move closer to BLA submission, I guess I was trying to get your thoughts on how you think about ReNu's positioning within the broader knee OA treatment landscape? And I guess, what you guys view as the key differentiators versus existing injectable options?

I think what's really exciting is the actual data. So in both studies, we had a significant number of KL4s in the study. So the second study hasn't been completed yet, but in the first study, those KL4s performed similar to KL3s and KL2s. So that is unique and it speaks to the strength of the product and potential labeling improvements in the product over anything else. So we're pretty excited that the data is showing that it's a robust product and will compete extremely well against the other competitors, which is primarily hyaluronic acid and steroids.

That's helpful. I have one more question regarding the Surgical and Sports segment of the business. I would like to understand what contributed to the strong performance in this quarter and how you anticipate maintaining this momentum for the remainder of the year.

Yes, sure. We didn't adjust the guidance there. I think we did see some very strong performance. I think you're seeing some transition into some of the key products that we've got in the portfolio. And so we continue to see some nice numbers coming up from there. In addition to that, we've kind of implemented some hybrid rep situations where you're really seeing reps spanning across both Wound Care and Surgical and that added some value in the quarter as well. So we held that guidance but it's between 6% and 23%. So nice performance in the first half, up 16% in the quarter and 13% for the half. So we're excited to see that.

We are currently showing no remaining questions in the queue at this time. That does conclude our conference for today. Thank you for your participation.